Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent

Kim J., Kudisch M., da Silva N.R.K., Asada H., Aya-Shibuya E., Bloomer M.M., Mudumba S., Bhisitkul R.B., Desai T.A.

2018
Journal of Controlled Release

View publication

Therapeutic Area

Glaucoma
Technology

Drug Delivery

Affiliations

UC Berkeley-UCSF Graduate Program in Bioengineering, 1700 4th Street, San Francisco, CA 94158, United States; Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143, United States; Santen Pharmaceutical Co., Ltd., Nara RD CenterNara, Japan; Santen, Inc., 6401 Hollis Street, Suite 125, Emeryville, CA 94608, United States; Department of Bioengineering and Therapeutic Sciences, University of California, 1700 4th Street, San Francisco, CA 94158, United States

Related Publications

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

The rate of failure of trabeculectomy and tube shunt surgery in eyes with uveitic glaucoma and ocular hypertension: The purpose of this study is to look at the outcomes of trabeculectomy and tube shunt surgery in a large cohort of patients with uveitis

Groth S.L.; Newcomb C.W.; Yang W.; Payal A.; Begum H.; Khachatryan N.; Kaçmaz R.O.; Dreger K.A.; Rosenbaum J.T.; Nida Sen H.; Suhler E.B.; Thorne J.E.; Bhatt N.P.; Foster C.S.; Jabs D.A.; Levy-Clarke G.A.; Buchanich J.M.; Ying G.S.; Kempen J.H.; Gangaputra S.;

View all Glaucoma publications